Education and Experience
Dr. Tülay Omma, Associate Professor
Specialization: Endocrinology and Metabolic Diseases
Academic Background
Professional Experience
Scientific Contributions & Publications
Awards & Recognitions
Professional Memberships & Certifications
Clinical & Research Focus
Dr. Omma’s expertise spans:
After the internal medicine examination, he also practiced in the United Kingdom, mainly treating patients with diabetes and endocrinological problems.
Diploma:
Professional exam:
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Education
2002 Haydarpaşa Numune Training and Research Hospital, Internal Medicine
1990 Erciyes University, Faculty of Medicine
Experience
2019 - 2019 Okan University Hospital
2018 - 2019 Ibn Sina Hospital
2003 - 2018 Pendik State Hospital
1997 - 2003 Haydarpasa Numune Hospital
1990 - 1994 Erzincan State Hospital
Istanbul Haydarpasa Numune Hospital
Kartal Health Group Presidency
Yıldırım Beyazıt Mother and Child Health Physician
Dr. Philipp Riss is the Team Leader in Surgical Endocrinology at the Medical University of Vienna. He specializes in general and visceral surgery. Dr. Riss earned his Doctorate in Medicine in 2005. He is a Senior Physician and a University Professor. He leads the Surgical Endocrinology Working Group. Dr. Riss has also organized several major international congresses.
He has received the Venia Docendi Award and the Sandoz Award for Thyroid Research. Dr. Riss is a member of leading societies, such as the European Society of Endocrine Surgeons and the International Society of Surgery. He also serves on advisory boards for neuroendocrine and endocrine surgery in Austria.
Dr. Elnur Sahibov is a licensed Radiation Oncologist with 8 years of medical training and clinical experience. He completed his undergraduate and specialization studies at Marmara University Faculty of Medicine. From 2012 to 2016, he focused on advanced radiation oncology techniques.
Dr. Sahibov is known for his expertise in cancer treatment. He has helped improve patient outcomes and uses evidence-based protocols. He is accredited by leading medical institutions and is dedicated to ongoing professional development in oncology.
Dr. Raj Nagarkar is a leading Surgical Oncologist with 19 years of experience. He has performed over 50,000 cancer surgeries. His main focus areas are Breast and Thoracic Surgical Oncology. He is involved in more than 200 clinical trials and has contributed to many national and international publications.
Dr. Nagarkar trained in Surgical Oncology at Tata Memorial Hospital, Mumbai. He also holds an MRCS from the Royal College of Surgeons, Edinburgh. He teaches DNB Superspecialty Surgical Oncology and Breast Surgery at Maharashtra University of Health Sciences. Dr. Nagarkar is dedicated to improving the quality of life for his patients.
Dr. Mucahit Gur is an Internal Medicine Specialist. He focuses on Diabetes Mellitus, Hypertension, Obesity, Hyperlipidemia, and Thyroid Diseases. He received his medical degree from Cerrahpaşa Faculty of Medicine. He completed his specialization in Internal Diseases at Düzce University.
Dr. Gur has worked at Tokat Niksar State Hospital, Düzce University, and Tokat Zile State Hospital. He currently practices at Emsey Hospital. He is known for his expertise in metabolic and endocrine disorders. Dr. Gur uses evidence-based methods and is dedicated to providing high-quality care.
Education
İnönü Üniversitesi Tıp Fakültesi (ingilizce) 1995- 2002
Work Experience
Başbakanlık S.H.Ç.E.K. Genel Müdürlüğü Kurum Hekimliği (2003)
Erciyes Üniversitesi Tıp Fakültesi Genel Cerrahi Uzmanlığı 2011
Yüzüncü Yıl Üniversitesi Temel ve İleri Düzey Endoskopik Girişimler Eğitimi 2011
İstanbul Hastanesi /Van 2011
Özel Malatya Hastanesi / Malatya2012
Bilgi Tıp Merkezi Keçiören /Ankara 2013
Özel Koru Sincan Hastanesi Sincan/Ankara 2013
Baş Tibb Mərkəzi /Baku Clinic Azerbaycan/Bakü 2013
Yüksek İhtisas Üniversitesi Özel Koru Ankara Hastanesi 2019
Özel Ankara Koru Hastanesi /Ankara 2019
Medical Interests
laparoscopic obesity
Laparoscopic abdominal and inguinal hernia repairs (with the latest techniques)
Postpartum laparascopic diastasis recti (the formation of a protrusion in the upper middle abdomen due to the separation of the muscles in the abdominal tissue) and abdominal hernias above the navel and and gobekustunde both diastasis recti repair and abdominal hernia repair from the skin with laparascopic scola method for the first time in Turkey laparascopic stomach hernia and antireflu surgery).
Laparoscopic gallbladder surgeries, including cleaning the bile duct with trans-cystic choledochal irrigation in patients with bile sludge and stones less than 5mm in the bile duct, performed in the same session
Laparoscopic gallbladder surgeries in pregnant women during the 2nd and 3rd trimesters, i.e., after 12 weeks of pregnancy
Laparoscopic Appendectomy in Pregnancy
Anal disorders, anal fissures, all types of internal and external hemorrhoid surgeries, anal fissure, and anal fistula surgeries
Thyroid surgeries and cancers, parathyroid surgeries and cancers
Breast diseases and breast cancer surgery
Oncological surgery; liver and gallbladder and bile duct surgeries, stomach cancer surgery, colon cancer surgery, and liver resections for metastatic liver tumors
Dr. Miroshnyk Tetyana Valeriivna is an endocrinologist with 22 years of clinical experience. She treats endocrine disorders using modern protocols. Her focus is on conservative treatment and long-term care for chronic conditions.
She provides consultations, diagnosis, and ongoing management of endocrine diseases. Her areas of expertise include type 1 and type 2 diabetes, diabetes insipidus, thyroid and adrenal disorders, metabolic syndrome, obesity, and metabolic imbalances.
Dr. Miroshnyk is known for her personalized approach and use of evidence-based methods. She is dedicated to improving patients’ quality of life by preventing complications and tailoring therapy to each individual.
Dr. Kubilay Ukinc is a specialist in endocrinology and metabolic diseases. His clinical interests include diabetes, thyroid disorders, obesity, and hypertension. He also treats adrenal and pituitary diseases, as well as hormone-related disorders in both women and men. Dr. Ukinc has expertise in low blood sugar conditions.
He received his medical training at Hacettepe University and Karadeniz Technical University. He has worked in academic and clinical roles at Karadeniz Technical University, Çanakkale Onsekiz Mart University, and Istanbul Bilim University. Dr. Ukinc has broad experience in internal medicine and endocrinology. He is active in both patient care and medical education.
Dr. Gonul Catli is a pediatric endocrinologist with over 20 years of experience. She specializes in childhood hormonal and metabolic disorders. Her areas of focus include diabetes, thyroid diseases, growth problems, and puberty issues. She received her training at Ankara University and Dokuz Eylul University. Dr. Catli has also worked as an Associate Professor at Izmir Katip Celebi University.
Dr. Catli is known for her scientific work and caring approach. She currently practices at Liv Hospital Ulus and Vadistanbul. She is a member of the European Society of Pediatric Endocrinology (ESPE) and several national associations. Dr. Catli is dedicated to using new treatments to support children’s health and well-being.